Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that combining vertical and transverse sections of scalp biopsy specimens improves diagnostic yield for certain hair disorders without increasing costs.

This source reviews recent research on Ginkgo biloba, highlighting its medicinal benefits due to compounds in the leaves and concerns over toxic alkylphenols in seeds. It also discusses patents for its food production uses and ongoing studies on toxicity and drug interactions.

This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.

This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.

This study found that hair thickness and density increased after treatment with human follicle mesenchymal stem cells and platelet rich plasma, associated with enhanced Wnt signaling and platelet derived growth factors.

This study found that people with alopecia who worry about not wearing a wig reported higher levels of depression, anxiety, and social anxiety, although wig use increased social confidence for many.

This research highlights that psychological stress can adversely affect hair growth in mice, implicating potential pathways that may be relevant in understanding stress-induced hair growth inhibition in humans.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This review discusses rodent models of alopecia areata and highlights genetic and epigenetic factors influencing its development, but reports no new experimental results.

This case report describes the topical application of cyclosporine in a man with alopecia universalis, which showed hair regrowth after 10 months of daily use, except where limited by a congenital nevus.

This review discusses what is known about the pathobiology of frontal fibrosing alopecia and reports no new clinical findings, highlighting potential environmental and genetic factors in disease pathogenesis.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This review outlines the role of dermal fibroblasts in wound healing and highlights their potential in developing new cellular therapies, but reports no new clinical results.

This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.

This study found that overexpression of the mineralocorticoid receptor in a mouse model led to premature epidermal barrier development, keratinocyte apoptosis, and postnatal alopecia, indicating new roles for MR signaling in skin physiology.

This study found that mice deficient in ceramide synthase 4 showed altered sebum composition and progressive hair loss due to obstructed hair canals.

This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study concluded that a polarized-light handheld dermatoscope attached to a digital camera is a practical and useful tool for diagnosing different types of alopecia.

This study suggests that an immune response to trichohyalin and keratin 16 may contribute to the pathogenesis of alopecia areata.

This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.

This report discusses guidelines for designing alopecia clinical trials that account for variables affecting results, but it presents no new efficacy findings.